These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 12601486)

  • 1. Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: correlation with CD38/CD138 expressing myeloma cells.
    Ak I; Aslan V; Vardareli E; Gülbaş Z
    Ann Hematol; 2003 Feb; 82(2):88-92. PubMed ID: 12601486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
    Ak I; Gulbas Z
    Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
    Kara IO; Sahin B; Paydas S; Cetiner S
    Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
    Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
    Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technetium-99m 2-methoxy-isobutyl-isonitrile uptake scintigraphy in detection of the bone marrow infiltration in multiple myeloma: correlation with MRI and other prognostic factors.
    Erten N; Saka B; Berberoglu K; Turkmen C; Unal S; Bakir B; Yekeler E; Besisik SK
    Ann Hematol; 2007 Nov; 86(11):805-13. PubMed ID: 17684742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma.
    Fonti R; Del Vecchio S; Zannetti A; De Renzo A; Di Gennaro F; Catalano L; Califano C; Pace L; Rotoli B; Salvatore M
    Eur J Nucl Med; 2001 Feb; 28(2):214-20. PubMed ID: 11303893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different patterns of technetium-99m sestamibi uptake in multiple myeloma.
    Pace L; Catalano L; Pinto A; De Renzo A; Di Gennaro F; Califano C; Del Vecchio S; Rotoli B; Salvatore M
    Eur J Nucl Med; 1998 Jul; 25(7):714-20. PubMed ID: 9662593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
    Rigolin GM; Tieghi A; Ciccone M; Bragotti LZ; Cavazzini F; Della Porta M; Castagnari B; Carroccia R; Guerra G; Cuneo A; Castoldi G
    Br J Haematol; 2003 Mar; 120(6):953-9. PubMed ID: 12648064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of F-18 fluorodeoxyglucose bone marrow uptake in patients with recent diagnosis of multiple myeloma: a comparative study with Tc-99m sestamibi.
    Castellani M; Carletto M; Baldini L; Calori R; Longari V; Soligo D; Dellavedova L; Gerundini P
    Clin Nucl Med; 2010 Jan; 35(1):1-5. PubMed ID: 20026963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS.
    Giovanella L; Taborelli M; Ceriani L; Zucca E; Cavalli F; Delaloye AB
    Nucl Med Commun; 2008 Jun; 29(6):535-41. PubMed ID: 18458600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
    Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
    Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease.
    Balleari E; Villa G; Garrè S; Ghirlanda P; Agnese G; Carletto M; Clavio M; Ferrando F; Gobbi M; Mariani G; Ghio R
    Haematologica; 2001 Jan; 86(1):78-84. PubMed ID: 11146575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scintigraphy with technetium-99m methoxyisobutylisonitrile in multiple myeloma patients: correlation with the International Staging System.
    Koutsikos J; Grigoraki V; Athanasoulis T; Velidaki A; Mamoulakis C; Zomas A; Anagnostopoulos N; Georgiou E; Dimopoulos MA; Zerva C
    Hell J Nucl Med; 2006; 9(3):177-80. PubMed ID: 17160159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the P-glycoprotein expression by 99mTc-MIBI bone marrow imaging in patients with untreated leukaemia.
    Ak I; Aslan V; Vardareli E; Gülbaş Z
    Nucl Med Commun; 2003 Apr; 24(4):397-402. PubMed ID: 12673168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double CD38
    Mykytiv V; Alwaheed A; Mohd Hashim NA
    Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):64-66. PubMed ID: 29079129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies.
    Kraj M; Pogłód R; Kopeć-Szlezak J; Sokołowska U; Woźniak J; Kruk B
    Leuk Lymphoma; 2004 Nov; 45(11):2281-9. PubMed ID: 15512818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tc-99m MIBI scintigraphy in multiple myeloma: prognostic value of different Tc-99m MIBI uptake patterns.
    Bacovsky J; Myslivecek M; Scudla V; Koranda P; Buriankova E; Minarik J; Pika T; Zapletalova J
    Clin Nucl Med; 2010 Sep; 35(9):667-70. PubMed ID: 20706038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of Tc-99m sestamibi scintigraphy in the detection of bone lesions in multiple myeloma: comparison with Tc-99m methylene diphosphonate.
    Alexandrakis MG; Kyriakou DS; Passam F; Koukouraki S; Karkavitsas N
    Ann Hematol; 2001 Jun; 80(6):349-53. PubMed ID: 11475149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans.
    Mele A; Offidani M; Visani G; Marconi M; Cambioli F; Nonni M; Catarini M; Brianzoni E; Berbellini A; Ascoli G; Brunori M; Agostini V; Corvatta L; Isidori A; Spinelli A; Gradari M; Leoni P
    Br J Haematol; 2007 Mar; 136(5):729-35. PubMed ID: 17233770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between the uptake of Tc-99m-sestaMIBI and prognostic factors in patients with multiple myeloma.
    Alexandrakis MG; Kyriakou DS; Passam FH; Malliaraki N; Christophoridou AV; Karkavitsas N
    Clin Lab Haematol; 2002 Jun; 24(3):155-9. PubMed ID: 12067279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.